Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.8% | 6.1% | -6.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 69% | 58.8% | 59.3% | 70.5% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -46.2% | 2.3% | -83% | -88.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -76.7% | -15.6% | -114.1% | -138.8% |
| EPS Diluted | -0.51 | -0.13 | -1.12 | -1.85 |
| % Growth | -292.3% | 88.4% | 39.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |